INVO Receives FDA Clearance For Expanded Use Of The INVOcell Device
Portfolio Pulse from Benzinga Newsdesk
INVO Bioscience has received FDA clearance for the expanded use of its INVOcell device, now cleared for a 5-day incubation period. The supporting data shows improved patient outcomes, similar to IVF.
June 27, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INVO Bioscience's INVOcell device receives FDA clearance for expanded use, allowing a 5-day incubation period. This could lead to increased adoption and sales.
The FDA clearance for expanded use of INVOcell device allows for a 5-day incubation period, which is supported by data showing improved patient outcomes. This could make the device more attractive to healthcare providers and patients, potentially leading to increased adoption and sales for INVO Bioscience.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100